Indivior Share Discussion Threads

[casholaa] 09/7/2024 15:16

I was just thinking that an 820p close on the way back up to 1200p would be welcome

[gonuts1] 09/7/2024 15:14

800p coming

[glasgow13] 09/7/2024 14:44

management shysters.

[gregmorg] 09/7/2024 14:41

well today the recent slide in share price has been explained but that in itself does cause me to question the management explanations and its grip.

[casholaa] 09/7/2024 14:17

You reminded me of a lyric in a track by Lord Tracy... East Coast Rose.... 'drop and give me 20'

[dealy] 09/7/2024 13:39

The CEO is very details driven.He has numbers on the tip of his tongue. General message is one of lumpiness with regard to patient numbers (roll on / roll off effects) and unevenness of Medicaid insurance timing etc.On thr litigation settlement: feels this was a good deal.for shareholders (avoids trial risk), 5/7 insurance are covered by this settlement, the remaining 2 are early stage claims only at this point.On Perseris discontinuation: I didn't understand or remember what he said, other than commiting to help those affected

[casholaa] 09/7/2024 13:39

That's what I was thinking. It may have started already too!

[swinsco] 09/7/2024 13:36

I expect the yanks will want the days lows before a turn up.

[casholaa] 09/7/2024 13:29

Sharp or slim, I just can distinguish in the state I am in

[dealy] 09/7/2024 13:26

on the subject of buybacks, the CEO said, "Given the share price" they will "actively assess" the use of cash (which seems to imply they will allocate more cash to buy backs)

[swinsco] 09/7/2024 13:26

Would be interested in your general thoughts once it's over, Dealy. Thanks.

[dealy] 09/7/2024 13:14

CEO sounds razor sharp

[swinsco] 09/7/2024 13:12

Webinar must be going well then!

[gonuts1] 09/7/2024 12:13

It took plenty at sub 700, averaging 693p; it went down to 663, and MMS was hitting bid. It would be nice to sell at 850p.

Plenty from my CPX profit.

[sbb1x] 09/7/2024 12:11

Ask moving up now....

[grupo] 09/7/2024 11:55

Indivior cuts jobs and discontinues sales of schizophrenia medication

By This Is Money
DAILY MAIL

Updated: 11:38 BST, 9 July 2024


Indivior shares nosedived on Tuesday after the drugmaker slashed its profit guidance and revealed it would discontinue sales of a schizophrenia drug.

The group, which switched its primary listing to the US last month but continues to trade on the FTSE 250, told investors it would cut 130 jobs related to the discontinuation of sales of Perseris.

Mark Crossley, chief executive, said expectations of higher payer management related to Perseris made production 'no longer financially viable' and so it would be discontinued.


Indivior will continue to supply Perseris to avoid patient care disruption for the foreseeable future, but said it will no longer deploy a dedicated sales force.

Indivior shares were down 38.7 per cent to 723.5p in early trading in London on Tuesday, having lost around 50 per cent over the last year.

The firm also told shareholders that net revenue for its opioid disorder drug Sublocade continues to be weak, due primarily to the elimination of Covid-19 emergency measures related to automatic Medicaid coverage renewals in the US.




Crossley said: 'As we look to the second half of the year, the US government has extended renewal allowances for certain States which will further delay the annualisation of this significant headwind.

'We are therefore reducing our FY 2024 guidance to reflect these impacts.'

But Crossley added that Indivior remains 'firm in our conviction that Sublocade's unique profile to address high-powered synthetic opioids', such as fentanyl, provides the group with 'a tremendous opportunity to meet the growing and changing needs of patients'.

He said: 'As a result, we continue to be confident that Sublocade will achieve a net revenue run rate of $1billion as we exit 2025 and ultimately meet our target of greater than $1.5billion in peak annual net revenue, underpinning the successful delivery of our medium-term profitable growth ambitions.'

[casholaa] 09/7/2024 11:09

Emergent BioSolutions among others also make narcan

[7rademark] 09/7/2024 10:49

Furthermore the company would have certainly not expected this % fall given they have been buying their shares back at higher prices recently and just yesterday. I would imagine they are buying heavily as we speak.

[7rademark] 09/7/2024 10:46

These markets honestly. 40% down is overdone when you work out the reduction in mcap. Given the recent fall in share price I just can not see the justification for it. I would expect a considerable recovery today.

[baddeal] 09/7/2024 10:35

Yep I have shares in both as well. Quite a day

[dealy] 09/7/2024 10:31

Story of 2 of my holdings today: Capita and Indivior. Capita has an amazing event (disposal worth as much as the entire market cap) and it goes up only 20%Indivior down 43% on its news.The red is always redder than the blue is bluer

[tsmith2] 09/7/2024 09:55

would agree. it's a good company. bought in

[dealy] 09/7/2024 09:44

interesting. is there a relationship between narcan and indivior ?

[casholaa] 09/7/2024 09:34

This is worth having a look at...